ChiralStar

ChiralStar is a clinical-stage biotechnology company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company leverages its proprietary ChiralStar asymmetric synthesis platform to overcome the challenges of creating complex chiral molecules, which are often difficult to manufacture at scale. ChiralStar's lead program, CS-01, is an oral small molecule GLP-1 receptor agonist currently being evaluated in Phase 1 clinical trials for the treatment of metabolic disorders such as obesity and type 2 diabetes. By focusing on oral alternatives to injectable therapies, the company aims to improve patient convenience and adherence in the rapidly growing metabolic disease market. In addition to metabolic health, ChiralStar is expanding its pipeline into oncology, utilizing its chemistry expertise to target previously undruggable pathways.